Introduction {#s0001}
============

Numerous resistance mechanisms of first and third generation EGFR TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) have been elucidated, with *EGFR-T790M* being the most commonly acquired resistance mutation.[@cit0001] As a third generation EGFR-TKI, osimertinib has demonstrated significant efficacy against *T790M* mutation.[@cit0002] However, acquired resistance to osimertinib after treatment inevitably arises, of which mechanisms include acquired *C797S* mutation and *BRAF^V600E^* mutation.[@cit0003],[@cit0004] Currently, the standard treatment for acquired *C797S* mutation is still under debate. As for the *BRAF^V600E^* mutation, a pre-clinical study and a case study[@cit0005],[@cit0006] have proven that combining *BRAF* or *MEK* inhibitor with osimertinib at the same time could exert a significant inhibitory effect on this acquired resistance. However, the progression-free survival (PFS) of treatment regarding *BRAF* or *MEK* inhibitor plus osimertinib was unclear.

Herein, we report the first clinical evidence of efficacy generated by a combination of dabrafenib plus trametinib and osimertinib to target concurrent *EGFR-19del, T790M,* and *BRAF^V600E^* in a lung adenocarcinoma patient. Furthermore, liquid biopsy at disease progression showed a new acquired mutation, *C797S in cis*, in addition to the original mutation after treatment. Subsequently, brigatinib and cetuximab were administered but without obvious response. Combination treatment of apatinib and osimertinib was applied and the therapeutic effect has been evaluated. The whole course of treatment and changes of tumor indicators during the treatment are shown in [Figures 1](#f0001){ref-type="fig"} and [2](#f0002){ref-type="fig"}, respectively.Figure 1Flowchart of the whole course of treatment.Figure 2Line chart of the changes of tumor markers during the process of the treatment. (**A**) Changes of CA-125 and CA-199 from Apr 2016 to Jun 2019. (**B**) Changes of CEA from Apr 2016 to Jun 2019.

Case Report {#s0002}
===========

A 63-year-old man with more than 40-year history of second-hand smoking presented with recurrent pain in his left lumbar back for more than half a year, and was diagnosed with stage IV lung adenocarcinoma with metastases to the spine ([Figure 3A](#f0003){ref-type="fig"}). Owing to the detection of *EGFR-19 del* by tissue biopsy, gefitinib (250 mg qd) was administered in April 2016. In addition, the magnetic resonance imaging (MRI) after 4 months of gefitinib treatment showed the patient reached a stable disease (SD) ([Figure 3B](#f0003){ref-type="fig"}). But his disease progressed after a progression-free survival (PFS) of 17 months and an MRI scan revealed the deterioration of bone metastasis ([Figure 3C](#f0003){ref-type="fig"}). At disease progression, his liquid biopsy revealed an *EGFR-T790M* mutation. Subsequently, the patient was treated with osimertinib (80 mg qd), and achieved a stable disease (SD) after 4 months based on criteria in Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 ([Figure 3D](#f0003){ref-type="fig"}). However, after 12 months of treatment with osimertinib, the patient's left lumbar back recurred. Results from computed tomography (CT) of his lung and MRI of his lumbar showed that the disease progressed ([Figures 3E](#f0003){ref-type="fig"} and [4A](#f0004){ref-type="fig"}). Subsequently, the patient was recommended for chemotherapy, but he refused due to a fear of a series of adverse events. In this case, we advised him to take a plasma next-generation sequencing (NGS) testing, and eventually, a *BRAF^V600E^* (AF=8.78%) mutation was identified in addition to *EGFR-19 del* and *EGFR-T790M* (AF=2.38%) mutation ([Figure 5A](#f0005){ref-type="fig"} and [B](#f0005){ref-type="fig"}).Figure 3Magnetic resonance imaging (MRI) scan regarding the clinical response of metastatic spine lesions during whole course of treatment. (**A**) Baseline MRI scan of the patient with spinal metastasis before the combination treatment. (**B**) Observation of stable disease (SD) after four-month gefitinib treatment. (**C**) Observation of the deterioration of the spine metastasis before osimertinib treatment. (**D**) Observation of stable disease (SD) after four-month osimertinib treatment. (**E**) Observation of progressive disease (PD) before the combination treatment of osimertinib and dabrafenib plus trametinib. (**F**) Observation of progressive disease (PD) after the nine-month combination treatment of osimertinib and dabrafenib plus trametinib.**Note:** Red arrow indicates spinal metastasis.Figure 4Computed tomography (CT) scan regarding clinical response of multi-drug combination of targeted therapy. (**A**) Baseline CT scan of the patient before the combination treatment. (**B**) Observation of stable disease (SD) after two-month combination treatment. (**C**) Observation of continuing therapeutic response after four-month combination treatment. (**D**) Observation of progressive disease (PD) manifested as enlarged pulmonary lesion and metastases after nine-month combination treatment. (**E**) Observation of SD after one-month combination treatment. (**F**) Observation of continuing SD after three-month combination treatment.**Note:** Red arrow indicates the lesion in the thorax.Figure 5Dynamic monitoring of integrative genomics viewer (IGV) regarding the acquired resistance mutations during the combination treatment. (**A**) Integrated genomics viewer showing the 1799T\>A at codon V600E (BRAF V600E) mutation (red) before combination treatment. (**B**) Integrated genomics viewer highlighting the presence of the 2369C\>T at codon 790 (EGFR-T790M) mutation (red) without accompanying with EGFR-C797S mutation before combination treatment. (**C**) Integrated genomics viewer showing the 1799T\>A at codon V600E (BRAF V600E) mutation (red) after combination treatment. (**D**) At disease progression, integrative genomics viewer highlighting the 2369C\>T at codon 790 (EGFR-T790M) mutation (red) oriented in cis with a 2389T\>A at codon 797 (EGFR-C797S) mutation (green) and 2390G\>C at codon 797 (*EGFR*-C797S) mutation (blue).

Due to the lack of recommendation for the subsequent treatment from the National Comprehensive Cancer Network (NCCN) guideline of Non-Small Cell Lung Cancer (Version 2017) at that time, we conducted a literature review to identify the optimal treatment strategy for the patient. A Phase 2 trial showed substantial anti-tumor activity and acceptable toxicity of dabrafenib plus trametinib in patients with treatment-naïve *BRAF^V600E^* mutation in advanced NSCLC[@cit0007] and a pre-clinical study[@cit0006] demonstrated that combined *BRAF* inhibitor with osimertinib might be a feasible treatment strategy for these triple mutations.

Therefore, a combination treatment with osimertinib (80 mg qd) and dabrafenib (150 mg bid) plus trametinib (2 mg qd) was administered with the consent of the patient in September 2018. As a result, the patient's back pain relieved significantly within two weeks. The follow-up CT reexamination also demonstrated his lung lesions decreased and reached SD ([Figure 4B](#f0004){ref-type="fig"} and [C](#f0004){ref-type="fig"}). Furthermore, he reached a remarkable PFS of 9 months, which was rarely reported for this therapeutic regimen recently. Notably, although the patient was treated with a multi-drug combination therapy, only mild adverse reactions such as intermittent low fever and paronychia occurred during the treatment.

In June 2019, he returned to the clinic due to recurring back pain. CT scan and MRI showed an enlarged pulmonary lesion together with metastases in subcarinal lymph node and the aggravation of bone metastases lesions, respectively ([Figures 3F](#f0003){ref-type="fig"} and [4D](#f0004){ref-type="fig"}). Liquid biopsy of plasma revealed the acquired mutation of *EGFR cis-C797S* (AF=6.17% and 7.76%), in addition to the original mutations (*19Del/T790M/BRAF^V600E^*) ([Figure 5C](#f0005){ref-type="fig"} and [D](#f0005){ref-type="fig"}).

Fortunately, a combination of brigatinib and cetuximab was demonstrated to have signiﬁcant suppression effect on NSCLC cell lines with *EGFR-C797S* and *T790M* mutations by inhibition of phosphorylation of EGFR and the decreased expression of EGFR.[@cit0008] Moreover, Wang et al[@cit0009] reported that a combination of brigatinib and cetuximab reached a PFS of 9 months in an advanced lung adenocarcinoma patient with triple mutations (*EGFR-19del/C797S/T790M*). This evidence provided us with clues for the subsequent treatment option for this patient. Thus, the combination therapy mentioned above was changed to brigatinib (90 mg qd) together with cetuximab (250 mg/m^2^) from June 2019 to July 2019. But it was regrettable that no obvious response was observed and his bone pain persisted in the treatment process. Oxycontin (20 mg/q12h) was applied for bone pain remission. Another therapeutic regimen for our patient was imperative.

According to the previous report, combination therapy of TKI and angiogenic agents could help to overcome the resistance of TKI.[@cit0010] Recently, a Phase III clinical trial (NEJ026 trial) showed that TKI combined with angiogenic agents significantly prolong PFS in EGFR-positive advanced NSCLC patients compared with TKI alone.[@cit0011] Therefore, a combination treatment of apatinib and osimertinib was administered based on the patient's intention and accessibility of treatment considerations in mid-July 2019. Notably, his bone pain was significantly released within a week without taking oxycontin. In August and September 2019, a CT scan showed that the pulmonary lesion had shrunk and reached SD ([Figure 4E](#f0004){ref-type="fig"} and [F](#f0004){ref-type="fig"}). In December 2019, our patient returned to our department, and imaging examination, as well as liquid biopsy, was performed for therapeutic effect evaluation.

Discussion {#s0003}
==========

Here, we presented the first case of a lung adenocarcinoma patient with triple mutations reaching a remarkable PFS of 9 months and tolerant toxicity under the combination treatment of osimertinib and dabrafenib plus trametinib. In addition, an acquired *cis-C797S* mutation was also identified after the combination treatment.

Osimertinib and dabrafenib plus trametinib might be a great treatment option for NSCLC patients with triple mutations (*19Del/T790M/BRAF^V600E^*). According to the NCCN guideline, osimertinib and dabrafenib plus trametinib were recommended as the preferred therapy for EFGR mutations (*19Del/L858R/T790M*) and *BRAF^V600E^* mutation in NSCLC patients, respectively.[@cit0012] However, when it came to the triple mutations (*19Del/T790M/BRAF^V600E^*), the therapeutic effect of combined molecular targeted therapy is unclear.

Recently, Solassol et al[@cit0013] have reported a case regarding a 68-year-old female never-smoker with triple mutations (*19Del/T790M/BRAF^V600E^*) who experienced a comprehensive treatment including treatment of dabrafenib plus trametinib alternation with osimertinib. This patient was administered with dabrafenib plus trametinib alternation with osimertinib at the disease progression after two cycles of chemotherapy. The PFS of the patient was only 6 months. By contrast, the patient in our case was only administered with molecular targeted therapy during the whole disease course. Additionally, osimertinib and dabrafenib plus trametinib were applied together but not altered. Of note, the PFS of our patient after the combined treatment was 9 months with a benefit of 3 months longer than that of the aforementioned patient. Indeed, any survival benefit in post-line therapy of advanced NSCLC is noteworthy. The difference of PFS benefit might result from the different treatment plan through the disease course of patients. It seemed that the efficacy of combined molecular targeted therapy might be better than chemotherapy followed with targeted therapy in these triple mutations.

Subsequently, the *cis-C797S* mutation was found in our patient. *EGFR-C797S* mutation was regarded as an important common acquired mechanism leading to resistance to all covalent EGFR-TKIs and the compromised efficacy of osimertinib.[@cit0014],[@cit0015] Though the combination of brigatinib and cetuximab was considered as a promising therapy for concurrent mutations (*EGFR-19del/C797S/T790M*), it did not exert a curative effect on our patient. We speculated that the difference in treatment outcome might result from the difference in the mutation pattern, for there was another *BRAF^V600E^* mutation in our patient. Afterward, due to the lack of the subsequent treatment recommendation for our patient, a combination of apatinib and osimertinib was applied. Recently, a prospective study showed that apatinib combined with osimertinib could help to overcome the resistance of osimertinib, which reached a median PFS of 4 months.[@cit0016] The further therapeutic effect and survival benefit of this treatment on our patient has been evaluated.

Indeed, the post-line treatment options for advanced NSCLC patients with multiple gene mutations are controversial. Our case showed that osimertinib and dabrafenib plus trametinib could be a great treatment option for triple mutations (*19Del/T790M/BRAF^V600E^*) in NSCLC patients. Additionally, full management of treatment for patients with multiple gene mutations is needed. Treatment adjustment should be evidence-based and take the patient's intention, as well as the accessibility of the treatment into consideration.

Conclusion {#s0004}
==========

In conclusion, our case showed a remarkable PFS of 9 months with a combination of dabrafenib plus trametinib and osimertinib in lung adenocarcinoma harboring *EGFR-19del, T790M* and *BRAF^V600E^* before acquiring the *cis-C797S* mutation. This case could be clinical evidence and sheds some light for NSCLC patients with concurrent mutations (*19Del/T790M/BRAF^V600E^*). In addition, full management strategy of treatment NSCLC patients with multiple gene mutations and more studies to find the standard treatment for the acquired *cis-C797S* mutation in addition to triple mutation (*19Del/T790M/BRAF^V600E^*) are still needed.

We owe thanks to the patient and his family.
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